An open label clinical study to evaluate the efficacy and safety of Saberry capsules in adult male or female patients suffering from Non-alcoholic Fatty Liver Disease.

Sami Labs Limited0 个研究点目标入组 24 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Known history of hypersensitivity to herbal extracts or dietary supplements.
•2 Duration of jaundice greater than 3 months, steato hepatitis, advanced fibrosis, cirrhosis and other liver enzymes.
•3 Pregnant women, lactating women and women of child bearing potential not following adequate contraceptive measure, women who were found positive for urine pregnancy test.
•4 Patients who are on immuno modulatory drugs.
•5 Ongoing treatment with herbals or allopathic hepato protective drugs.
•6 Evidence of several renal, hepatic or hematopoietic disorders or severe cardiac insufficiency as revealed by laboratory investigations.
•7 History of having received any investigational drug or participated in any other clinical trial which ended in preceding month or currently ongoing.
•8 Ayurvedic formulation or any form of CAM therapy in the preceding 2 months.
•9 Any condition that in the opinion of the investigator does not justify the patients inclusion for the study.
•10 Patients who underwent liver transplantation.

发起方

Sami Labs Limited